This year's congress emphasized the importance of quality and innovation in the field, with a particular focus on Artificial Intelligence (AI) and its applications.
Mediq Finland, a silver partner at the event, played a crucial role in promoting these values with the Werfen portfolio in Acute Care Dx, Autoimmunity, and Hemostasis. Their presence highlighted the commitment to collaborating with healthcare leaders to drive advancements in laboratory practices.
The congress featured a diverse program, including sessions on the challenges and regulatory compliance of AI systems, the use of machine learning in identifying cancer risks, and the implementation of AI in healthcare. These discussions underscored the importance of continuous improvement and innovation in laboratory medicine.
Keynotes and discussions: The congress featured a range of keynote speeches and panel discussions, providing valuable insights into the latest trends and developments in laboratory medicine.
One key highlight was a session on the new EU AI Act, which sets a legal framework for assessing the risk of AI in medical devices. This session emphasized the importance of early planning and compliance with multiple legal frameworks.
In addition to the main program, the congress also featured a series of e-posters showcasing the latest research in the field. Topics covered included the use of AI in histopathology, the development of new drug testing methods, and the impact of digital health solutions.

EEMEA Marketing Hemostasis and Acute Care Team